Amantadine for COVID-19 treatment (ACT) study: a randomized, double-blinded, placebo-controlled clinical trial

Weis, Nina; Bollerup, Signe; Sund, Jon Dissing; Glamann, Jakob Borg; Vinten, Caroline; Jensen, Louise Riger; Sejling, Christoffer; Kledal, Thomas Nitschke; Rosenkilde, Mette Marie

doi:10.1016/j.cmi.2023.06.023

Cited by 4 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is noteworthy that the drug given too late in more advanced stages of COVID-19 may be ineffective as described in a recent study [16] that, however, has biases such as not controlling for age and previous exposure to vaccinations in the enrolled population. In another study with a similar design [27], vaccinated patients were included that did not have disease progression and thus the authors were unable to assess the effect of amantadine on the course of COVID-19. This can be explained by the strong protective effect of vaccination, which obviously diluted any possible activity of amantadine in a cohort of COVID-19 patients.…”

Section: Discussionmentioning

confidence: 99%

Amantadine in unvaccinated patients with early, mild to moderate COVID‐19: A randomized, placebo‐controlled, double‐blind trial

Rejdak

Fiedor

Bonek³

et al. 2023

Euro J of Neurology

View full text Add to dashboard Cite

Background and purposeAdamantanes were listed as interesting option as an early intervention against COVID‐19. We aimed to evaluate the effectiveness of amantadine in preventing the progression of COVID‐19 and its neurological sequelae.MethodsUnvaccinated patients with confirmed SARS‐CoV‐2 infection within 5 days were enrolled. Subjects were randomized (50:50) to amantadine (AMD, 100 mg BID) or placebo (PLB), for 14 days. WHO ordinary scale was the primary measure. The secondary endpoints included assessment for: fatigue; depression, disorders of smell and taste and sleepiness on Day 1 and 15.ResultsWe enrolled 99 patients (49 AMD and 50 PLB). Disease progression (WHO=4) was observed in 3 patients (6%) in AMD group, and in 4 patients (8%) in PLB (p>0.05). Complete recovery on Day 15 was 60% higher in AMD compared to PLB group (p = 0.025). There was improvement in taste (AMD: p = 0.003; PLB: p = 0.0001) and smell (AMD: p = 0.005; PLB: p = 0.0004) but not in fatigue in both groups. Improvement was observed in AMD (p = 0.010), but not in PLB group (p = 0.058) assessing depression as well as sleepiness (AMD, p = 0.0002; PLB, p = 0.341). There was one death case in the PLB group (2.0%) and none in the AMD group (p>0.05) until Day 210. Overall the drug was well tolerated.ConclusionsThe central effects on the nervous system with reduction of sleepiness and depression might have had a supportive effect on faster recovery in early COVID‐19 patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Amantadine in unvaccinated patients with early, mild to moderate COVID‐19: A randomized, placebo‐controlled, double‐blind trial

Rejdak

Fiedor

Bonek³

et al. 2023

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

Ultrasensitive SERS aptasensor using Au@Ag bimetallic nanorod SERS tags for the selective detection of amantadine in foods

Wang,

Chen,

Waterhouse

et al. 2024

Food Chemistry

View full text Add to dashboard Cite

Advancing the field of viroporins—Structure, function and pharmacology: IUPHAR Review 39

Devantier,

Kjær,

Griffin

et al. 2024

British J Pharmacology

View full text Add to dashboard Cite

Viroporins possess important potential as antiviral targets due to their critical roles during virus life cycles, spanning from virus entry to egress. Although the antiviral amantadine targets the M2 viroporin of influenza A virus, successful progression of other viroporin inhibitors into clinical use remains challenging. These challenges relate in varying proportions to a lack of reliable full‐length 3D‐structures, difficulties in functionally characterising individual viroporins, and absence of verifiable direct binding between inhibitor and viroporin. This review offers perspectives to help overcome these challenges. We provide a comprehensive overview of the viroporin family, including their structural and functional features, highlighting the moldability of their energy landscapes and actions. To advance the field, we suggest a list of best practices to aspire towards unambiguous viroporin identification and characterisation, along with considerations of potential pitfalls. Finally, we present current and future scenarios of, and prospects for, viroporin targeting drugs.

show abstract

Amantadine for COVID-19 treatment (ACT) study: a randomized, double-blinded, placebo-controlled clinical trial

Cited by 4 publications

References 28 publications

Amantadine in unvaccinated patients with early, mild to moderate COVID‐19: A randomized, placebo‐controlled, double‐blind trial

Amantadine in unvaccinated patients with early, mild to moderate COVID‐19: A randomized, placebo‐controlled, double‐blind trial

Ultrasensitive SERS aptasensor using Au@Ag bimetallic nanorod SERS tags for the selective detection of amantadine in foods

Advancing the field of viroporins—Structure, function and pharmacology: IUPHAR Review 39

Contact Info

Product

Resources

About